Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenichi Suda

Showing results (71-80 of 127) with videos related to

Pageof 13
Sort By:
Cancers|May 13, 2023
Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular ScreeningKenichi Suda, Kazuko Sakai, Tatsuo Ohira, et al.
Lung Cancer (Amsterdam, Netherlands)|June 19, 2014
CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutationKenichi Suda, Hiroshi Mizuuchi, Isao Murakami, et al.
Scientific Reports|September 25, 2015
Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancerKenichi Suda, Isao Murakami, Kazuko Sakai, et al.
Cancer Treatment Reviews|November 17, 2018
EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysisFrancesco Agustoni, Kenichi Suda, Hui Yu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 21, 2009
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinibTatsuya Katayama, Junichi Shimizu, Kenichi Suda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2014
Prognostic and therapeutic implications of aromatase expression in lung adenocarcinomas with EGFR mutationsMikihiro Kohno, Tatsuro Okamoto, Kenichi Suda, et al.
Translational Lung Cancer Research|December 13, 2023
Long-term survival after stereotactic body radiotherapy combined with immunotherapy plus anti-angiogenesis therapy in patients with advanced non-small cell lung cancer and <i>EGFR</i> exon 20 insertion mutation: a report of two casesQiang Luo, Leichong Chen, Zhenyu Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2018
Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve LesionsKenichi Suda, Jihye Kim, Isao Murakami, et al.
Translational Lung Cancer Research|September 29, 2021
Activity and mechanism of acquired resistance to tarloxotinib in <i>HER2</i> mutant lung cancer: an <i>in vitro</i> studyTakamasa Koga, Kenichi Suda, Masaya Nishino, et al.
Surgery Today|February 21, 2021
The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgeryToshiki Takemoto, Junichi Soh, Shuta Ohara, et al.
Pageof 13

Showing results (71-80 of 127) with videos related to

Sort By:
Pageof 13
Cancers|May 13, 2023
Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular ScreeningKenichi Suda, Kazuko Sakai, Tatsuo Ohira, et al.
Lung Cancer (Amsterdam, Netherlands)|June 19, 2014
CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutationKenichi Suda, Hiroshi Mizuuchi, Isao Murakami, et al.
Scientific Reports|September 25, 2015
Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancerKenichi Suda, Isao Murakami, Kazuko Sakai, et al.
Cancer Treatment Reviews|November 17, 2018
EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysisFrancesco Agustoni, Kenichi Suda, Hui Yu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 21, 2009
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinibTatsuya Katayama, Junichi Shimizu, Kenichi Suda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2014
Prognostic and therapeutic implications of aromatase expression in lung adenocarcinomas with EGFR mutationsMikihiro Kohno, Tatsuro Okamoto, Kenichi Suda, et al.
Translational Lung Cancer Research|December 13, 2023
Long-term survival after stereotactic body radiotherapy combined with immunotherapy plus anti-angiogenesis therapy in patients with advanced non-small cell lung cancer and <i>EGFR</i> exon 20 insertion mutation: a report of two casesQiang Luo, Leichong Chen, Zhenyu Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2018
Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve LesionsKenichi Suda, Jihye Kim, Isao Murakami, et al.
Translational Lung Cancer Research|September 29, 2021
Activity and mechanism of acquired resistance to tarloxotinib in <i>HER2</i> mutant lung cancer: an <i>in vitro</i> studyTakamasa Koga, Kenichi Suda, Masaya Nishino, et al.
Surgery Today|February 21, 2021
The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgeryToshiki Takemoto, Junichi Soh, Shuta Ohara, et al.
Pageof 13